Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EPS (Basic) (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EPS (Basic) for 16 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 200.0% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.16 through Dec 2025, up 1700.0% year-over-year, with the annual reading at $0.15 for FY2025, 1400.0% up from the prior year.
  • EPS (Basic) hit -$0.01 in Q4 2025 for Ironwood Pharmaceuticals, down from $0.25 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.42 in Q2 2021 to a low of -$6.84 in Q2 2023.
  • Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of $0.2 in 2022.
  • Biggest five-year swings in EPS (Basic): plummeted 2950.0% in 2023 and later soared 1600.0% in 2025.
  • Year by year, EPS (Basic) stood at $0.25 in 2021, then grew by 28.0% to $0.32 in 2022, then tumbled by 103.12% to -$0.01 in 2023, then surged by 200.0% to $0.01 in 2024, then crashed by 200.0% to -$0.01 in 2025.
  • Business Quant data shows EPS (Basic) for IRWD at -$0.01 in Q4 2025, $0.25 in Q3 2025, and $0.15 in Q2 2025.